DEA's 7-OH Filing Contains a Critical Contradiction: The Written Rule Has No Natural Product Exemption

Why it matters

The DEA's verbal framing of the 7-OH scheduling action — that it only targets concentrated synthetic products — is contradicted by the written regulatory text, which contains no explicit natural botanical exemption. This gap between stated intent and written rule creates significant legal uncertainty for extract vendors and gives advocates a concrete, text-based argument to make during the 30-day public comment period that closes July 31.

The big picture

Two Notices of Intent were filed on July 1, 2026 and published July 6: one from DEA (DEA-1570) initiating temporary Schedule I placement, one from HHS opening the public comment period (HHS-OASH-2026-0232). DEA Administrator Terrance Cole verbally characterized the action as targeting "highly concentrated, synthetic 7-OH products." However, the written rule's threshold — more than 0.050% by dry weight OR more than 1 mg per serving — has no carve-out for naturally occurring 7-OH in botanical material. The DEA's own filing acknowledges that "consumers of raw plant matrix may experience a modified or attenuated physiological effect," a statement that simultaneously undercuts the rationale for scheduling natural leaf and highlights the gap in the written rule.

Key findings

• The DEA's written threshold targets both natural botanical material above 0.050% (Part A) and synthetic or processed products above 0.050% OR 1 mg per serving (Part B) — with no explicit text-based exemption for whole-leaf kratom
• Natural whole-leaf kratom typically tests at 0.01–0.02% 7-OH by dry weight, placing it below the Part A threshold — but the absence of a written exemption leaves enforcement to agency discretion
• Also being scheduled alongside 7-OH: mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16 — synthetic derivatives that do not occur naturally in the plant
• The 1 mg per serving limit under Part B captures most full-spectrum extract products regardless of their overall potency, even if their percentage concentration appears low
• Johns Hopkins researcher Kirsten Smith stated publicly: "We don't really have a public health signal of a lot of adverse events for either kratom or for 7-OH at this time" — an assessment not addressed in the DEA's filing
• The public comment docket (HHS-OASH-2026-0232) at regulations.gov closes July 31, 2026; comments are on the administrative record and can inform any subsequent legal challenge

What they say

The Kratom Truth Project analysis notes: "The DEA is acknowledging in its own filing that whole-leaf kratom is pharmacologically distinct from isolated 7-OH. That distinction — which the DEA and AKA are now jointly claiming justifies the scheduling — is nowhere reflected in the actual threshold language of the rule. That contradiction belongs in your public comment."

Bottom line

**Advocates have until July 31, 2026 to place on the formal administrative record the contradiction between the DEA's verbal framing and its written rule — a gap that could prove decisive in any future legal challenge to the temporary scheduling.**